UK markets close in 3 hours 35 minutes

Jupiter Emerging European Opportunities J Acc (0P0001JU9I.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
149.33+3.28 (+2.25%)
As of 09:00PM BST. Market open.
Full screen
Previous close146.05
YTD return-39.99%
Expense ratio (net)0.00%
CategoryEmerging Europe Equity
Last cap gain0.00
Morningstar rating★★★★★
Morningstar risk ratingAverage
Sustainability rating
Net assets82.88M
Beta (5Y monthly)0.99
Yield2.93%
5y average returnN/A
Holdings turnover166.28%
Last dividend0.00
Average for categoryN/A
Inception date29 May 2020
  • Globe Newswire

    Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook

    REGULATED INFORMATION Recruitment for ALLOB tibial facture Phase IIb study ongoing and on schedule to release topline data in Q1 2023, despite COVID slowdown New scientific advisory board appointments to bolster the further development of the next generation iMSCg platform Discussions for ALLOB global partnership still ongoing. Completion of potential global partnership delayed and now anticipated in Q1 2022 Financial position strengthened following equity fundraising in Q4 2021 with runway expe

  • Globe Newswire

    Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

    REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Gosselies, Belgium, 10 December 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 8 December 2021 indicating that the shareholdings held by Nyenburgh Holding NV have crossed above the threshold of 5% following the issuance of

  • Globe Newswire

    Bone Therapeutics SA: Information on the total number of voting rights and shares

    REGULATED INFORMATION Gosselies, Belgium, 9 December 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares in a private placement on 2 December 2021. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of